Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile

This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Boehringer Ingelheim GmbH: PharmaVitae Profile

This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Abbott Laboratories: PharmaVitae Profile

This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Eli Lilly & Co.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Eli Lilly in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

GlaxoSmithKline plc: PharmaVitae Profile

This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Multiple Sclerosis - Tysabri to prevail despite safety setbacks

Spurred by uptake of Biogen Idec and Elan's Tysabri (natalizumab) and continued revenue growth for the three beta-interferon brands and Teva's Copaxone (glatiramer acetate), the seven major multiple sclerosis market value increased 15.1% from 2006 to $5.3 billion in 2007.

Top 20 Therapy Cancer Brands - Key brands set to consolidate advantage as competition

Cancer therapy brand sales totaled over $30 billion in the seven major markets in 2007, growing by 20.1% since 2006. The high growth of this market makes it attractive to companies keen to emulate the blockbuster status achieved by several brands. However, with several impending patent expiries due, companies will need to work hard to maximize their return throughout the lifecycle of their brands.

Antihormonal Therapy Cancer Brands - Careful lifecycle management needed to preserve brand

Antihormonal therapies are a class of cancer therapeutics that generated branded drug sales of $5.8 billion in the seven major pharmaceutical markets in 2007. However, the relative maturity of the market means that it is has become a highly genericized therapeutic class. Even still, the lack of innovation within this saturated market helps many leading brands retain their success.

Insomnia - Orexin and serotonin receptor modulators to innovate market

After 3 years of steady growth, the value of the insomnia market across the seven major markets (7MM) slumped by 12% to $4.1 billion in 2007 due to rapid generic erosion of Sanofi-Aventis's market leader Ambien (zolpidem) in the US. However, this downturn will be short-lived and the market will regain growth from 2009 to $6.9 billion in 2017 driven by the launch of new treatments across the 7MM.

Commercial Insight: HIV - The battle for market share is getting fiercer

In 2007, HIV drugs achieved sales of $9.3 billion in the 7MM, growing faster than the overall market at a CAGR of 11.3% from 2004-2007. Due to patent expirations, Datamonitor expects the market's growth to slow down somewhat, reaching total sales of $15.1 billion in 2017. Among the ROW, the Canadian HIV market in 2007 was worth $272 million, achieving a CAGR of 24% from 2004-2007.

Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape

With sales growth rates expected to fall below their historic levels, Big Pharma must act to bolster its performance out to 2012 if it is to maintain the investment community's valuation of its stocks. One mechanism for plugging the sales growth rate gap and fulfilling investors' 'growth imperative' is M&A activity.

 Don’t Need Quality Patent Information?  Think Again…

Sydney, Australia 29th September, 2008.   A recent case heard in the Federal Court of Australia illustrates the need for comprehensive, accurate and regularly updated patent information to ensure that the planned launch of a generic pharmaceutical product is not delayed.

Embrace the eCTD and stay ahead

As one door closes, businesses must look for their next opening. Today, the traditional strongholds of the pharmaceutical industry, the US and Europe, are witnessing a downturn in growth to around 6% a year. This is the result not only of problems in the broader economy, but also the loss of marketing exclusivity by products in a number of major therapeutic categories; lower contributions from new products because of increased scrutiny of their value; and slower take-up by doctors and healthcare systems.

MARKET RESEARCH OF DRUGS USED AS LAXATIVES

Laxatives (or purgatives) are foods, compounds, or drugs taken to induce bowel movements or to loosen the stool, most often taken to treat constipation. Certain stimulant, lubricant, and saline laxatives are used to evacuate the colon for rectal and bowel examinations, and may be supplemented by enemas in that circumstance. Sufficiently high doses of laxatives will cause diarrhea. 

Whole 10 pages article is available for download at Repository  of Faramavita.Net 

Implementation of a New Category-

"OTC Medicinal Products Subject to Sales Restriction"

The State Institute for Drug Control (SÚKL) has been preparing the implementation of a new category of supply of medicinal products, “OTC medicinal products subject to sales restriction” on the grounds of provisions of Section 39 (3) of the new Act No 378/2007 Coll., on Pharmaceuticals and on Amendments to Some Related Acts, asamended (“Act on Pharmaceuticals”).

Whole 8 pages article is available for download at Repository of Faramavita.Net

Launching the Indian Generic Pharmaceutical Patent Academy – Understand and Respond to Patents

Sydney, Australia 10th September, 2008:  GenericsWeb is thrilled to announce that the Generic Pharmaceutical Patent Academy is travelling to India for two events:

STATUS AND CONSERVATION OF LEPIDIUM SATIVUM LINN. (CHANSUR): AN ETHNOMEDICINAL HERB OF MADHYA PRADESH

Herbal medicines are in great demand in both developed and the developing countries in primary healthcare because of their great efficacy and little or no side effects. In India, the indigenous system of medicine namely Ayurvedic, Siddha and Unani have been in existence for several centuries. These traditional systems of medicine together with homoeopathy and folklore medicine continue to play a significant role largely in the health care system of the population.

Whole 5 pages article is availabel for download at Repository of Faramavita.Net

If you would like to have meeting with us please send you proposal to info(at)farmavita.net.